Arm

Canada's tech sector fuels growth across the economy: BDC study

Retrieved on: 
Monday, January 31, 2022

Growth in the tech sector is expected to be 5.3% in 2022, and growth for the 2021-24 period is expected to be 22.4%.

Key Points: 
  • Growth in the tech sector is expected to be 5.3% in 2022, and growth for the 2021-24 period is expected to be 22.4%.
  • Entitled " Tech Industry Outlook: What's Next for the Technology Sector in Canada ", the tech sector is a key pillar of Canada's economy, driving growth across sectors and helping make other industries more productive.
  • Products and services from the tech sector will fuel much of the innovation and productivity that will power economic growth in the next decades.
  • The data used in this study is based on four BDC surveys conducted in 2021, as well as from an econometric analysis of growth from M&A in the tech sector.

Juvenescence Ltd. Portfolio Company Hails Successful Limb Regeneration in Adult Frogs

Retrieved on: 
Monday, January 31, 2022

Morphoceuticals Inc., a portfolio company of Juvenescence Ltd., hailed the results of a long-term study published by its founders in Science Advances showing the successful regeneration of limbs in Xenopus laevis (African clawed frog).

Key Points: 
  • Morphoceuticals Inc., a portfolio company of Juvenescence Ltd., hailed the results of a long-term study published by its founders in Science Advances showing the successful regeneration of limbs in Xenopus laevis (African clawed frog).
  • This is the first demonstration of functional limb regeneration in a species that does not show spontaneous regeneration of complex limbs in adulthood.
  • Juvenescence is excited for Morphoceuticals to continue developing a better understanding of how bioelectric patterning contributes to development and regeneration.
  • Using proprietary combinations of ion channel and gap junction modulators, we are focused on inducing limb regeneration, improving amputation stump health, promoting organ regeneration, and the treatment of channelopathies.

7 Mindsets Names Three New Senior Executives

Retrieved on: 
Thursday, January 27, 2022

ATLANTA, Jan. 27, 2022 /PRNewswire-PRWeb/ --7 Mindsets, the leading provider of online social-emotional learning (SEL) curriculum and professional development to schools and districts nationwide, recently announced the addition of three executives to its senior leadership team.

Key Points: 
  • ATLANTA, Jan. 27, 2022 /PRNewswire-PRWeb/ --7 Mindsets, the leading provider of online social-emotional learning (SEL) curriculum and professional development to schools and districts nationwide, recently announced the addition of three executives to its senior leadership team.
  • Baird brings over 25 years of experience in sales, operations, and product and project management experience to his new position.
  • Prior to 7 Mindsets, he served as senior vice president at Mindgrub Technologies, first steering its client solutions and operations and then moving on to operations at its investment arm, Mindgrub Ventures.
  • Before joining 7 Mindsets, he was senior vice president for Achieve3000 where he oversaw the organic growth and assimilation of the acquired Actively Learn curricular platform.

NucleiSys Adopts Breker’s System Coherency TrekApp

Retrieved on: 
Tuesday, January 25, 2022

SAN JOSE, Calif., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Breker Verification Systems today announced Nuclei System Technology deployed its System Coherency Synthesis TrekApp to ensure coherency of its configurable low-power and high-performance 32- and 64-bit RISC-V processor intellectual property (IP) designs.

Key Points: 
  • SAN JOSE, Calif., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Breker Verification Systems today announced Nuclei System Technology deployed its System Coherency Synthesis TrekApp to ensure coherency of its configurable low-power and high-performance 32- and 64-bit RISC-V processor intellectual property (IP) designs.
  • After an extensive evaluation, we choose Brekers System Coherency TrekApp to help to ensure our designs coherency, remarks JianYing Peng, CEO of Nuclei System Technology.
  • The System Coherency Synthesis TrekApp can generate thousands of high-coverage tests to stress cross-system coherency for a broad range of SoC platforms and processors.
  • It is based on Brekers Cache Coherency TrekApp and uses abstract models of common and novel algorithms to automatically generate coherency test content for complex, multi-agent system platforms based on coverage directives.

Me2B Alliance Research Exposes Poor Understanding Among Consumers Regarding Privacy Policies, Terms of Service, and Who They Protect

Retrieved on: 
Tuesday, January 25, 2022

SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Me2B Alliance, a non-profit independent testing and advocacy organization focused on safe and respectful technology, today published a Spotlight Report which uncovers a distinct lack of understanding among consumers regarding legal policies such as Terms of Service, Terms of Use, and privacy policies. Through qualitative and quantitative research, the Me2B Alliance explores that lack of understanding, and its implications on the validity and ethical standing of such legal policies.

Key Points: 
  • Through qualitative and quantitative research, the Me2B Alliance explores that lack of understanding, and its implications on the validity and ethical standing of such legal policies.
  • The Spotlight Report, Me2B Alliance Validation Testing Report: Consumer Perception of Legal Policies in Digital Technology , was originally initiated to understand if providing a formal rating of these legal policies (Terms of Service, Terms of Use and privacy policies) would be valuable to consumers.
  • Concern arose during the research process when it became clear that individuals did not know whether these policies are legally binding contracts.
  • The Me2B Alliances research makes clear that is not the case in Terms of Service agreements.

Vita Inclinata: "Technology Is Cheap, Lives Are Priceless" -- A True Helicopter Rescue Story Turned Horrific And The Technology To Solve It

Retrieved on: 
Thursday, January 27, 2022

It was all I could do not to just blackout," recalls Bowling, former Air Force Colonel and pilot.

Key Points: 
  • It was all I could do not to just blackout," recalls Bowling, former Air Force Colonel and pilot.
  • "Military men and women will risk their own lives to ensure their comrades are safe and return to see their loved ones again.
  • "Had this rescue gone very smoothly, the trauma I suffered would have been decreased by orders of magnitude," said Bowling.
  • Based in Broomfield, Colorado, Vita Inclinata Technologies Inc. includes Vita Aerospace and Vita Industrial.

TYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer

Retrieved on: 
Wednesday, January 26, 2022

TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), today announced the discontinuation of SM-88 with MPS in the Precision Promise trial in metastatic pancreatic cancer (mPDAC) upon learning from the trial sponsor, Pancreatic Cancer Action Network (PanCAN), that it terminated the arm due to futility compared to the control of standard of care chemotherapy in second-line mPDAC.

Key Points: 
  • TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), today announced the discontinuation of SM-88 with MPS in the Precision Promise trial in metastatic pancreatic cancer (mPDAC) upon learning from the trial sponsor, Pancreatic Cancer Action Network (PanCAN), that it terminated the arm due to futility compared to the control of standard of care chemotherapy in second-line mPDAC.
  • The Precision Promise trial is an adaptive randomized Phase 2/3 trial in mPDAC for patients treated in both first-line and second-line therapies.
  • Given pancreatic cancers high mortality rate, we wanted to make a difference in the lives of these patients.
  • A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer.

Acrisure and Oak View Group Announce 10-year Naming Rights for Coachella Valley Arena

Retrieved on: 
Thursday, January 27, 2022

"The Acrisure Arena reflects our commitment to raising awareness of the multiple financial solutions were proud to offer our customers.

Key Points: 
  • "The Acrisure Arena reflects our commitment to raising awareness of the multiple financial solutions were proud to offer our customers.
  • We are proud to announce our naming rights agreement with Acrisure, said Tim Leiweke, CEO of Oak View Group and leader of the arena project.
  • Acrisure and Oak View Group are dedicated to using this platform to improve the lives of everyone in the Coachella Valley.
  • The Acrisure Arena is a $250+ million project that is being 100% privately funded through outstanding partners Oak View Group, Seattle Kraken, and Live Nation.

Easterly Investment Partners’ All Cap Value Strategy Marks 30 Years

Retrieved on: 
Tuesday, January 25, 2022

The Easterly Investment Partners (EIP) All Cap Value Strategy celebrated its 30th anniversary on January 1, 2022.

Key Points: 
  • The Easterly Investment Partners (EIP) All Cap Value Strategy celebrated its 30th anniversary on January 1, 2022.
  • The All-Cap Value Strategy seeks to provide long-term capital appreciation through an equal-weighted portfolio of value equity securities across the entire market capitalization spectrum.
  • Easterly Investment Partners (EIP) is the traditional, fundamental based investment arm of Easterly Asset Managements multi-affiliate platform.
  • Disclaimer: The views expressed herein are solely the opinions of Easterly Investment Partners (EIP).

AIROS Medical and Fist Assist Devices, LLC Announce Launch of Commercial Website for Fist Assist FA-1 Wearable Medical Device

Retrieved on: 
Tuesday, January 25, 2022

AIROS Medical, Inc., a designer, manufacturer, and distributor of compression therapy devices, and Fist Assist Devices, LLC (Fist Assist), an innovative medical device company, today announced the launch of an e-commerce website, www.fistassistusa.com , for the sale of the Fist Assist FA-1 compression device.

Key Points: 
  • AIROS Medical, Inc., a designer, manufacturer, and distributor of compression therapy devices, and Fist Assist Devices, LLC (Fist Assist), an innovative medical device company, today announced the launch of an e-commerce website, www.fistassistusa.com , for the sale of the Fist Assist FA-1 compression device.
  • AIROS Medical is the exclusive distributor of the Fist Assist Model FA-1 device in the United States.
  • Fist Assist Devices, LLC and AIROS Medical formed a collaborative partnership in July of 2020.
  • AIROS is also the exclusive U.S. distributor of the Fist Assist Model FA-1 pneumatic compression device, available for sale at www.fistassistusa.com .